Addition  ||| S:0 E:9 ||| NN
of  ||| S:9 E:12 ||| IN
autologous  ||| S:12 E:23 ||| JJ
mesenchymal  ||| S:23 E:35 ||| NNS
stem  ||| S:35 E:40 ||| VBP
cells  ||| S:40 E:46 ||| NNS
to  ||| S:46 E:49 ||| TO
whole  ||| S:49 E:55 ||| JJ
blood  ||| S:55 E:61 ||| NN
for  ||| S:61 E:65 ||| IN
bioenhanced  ||| S:65 E:77 ||| JJ
ACL  ||| S:77 E:81 ||| NNP
repair  ||| S:81 E:88 ||| NN
has  ||| S:88 E:92 ||| VBZ
no  ||| S:92 E:95 ||| DT
benefit  ||| S:95 E:103 ||| NN
in  ||| S:103 E:106 ||| IN
the  ||| S:106 E:110 ||| DT
porcine  ||| S:110 E:118 ||| JJ
model  ||| S:118 E:124 ||| NN
Coculture  ||| S:124 E:134 ||| NNS
of  ||| S:134 E:137 ||| IN
mesenchymal  ||| S:137 E:149 ||| JJ
stem  ||| S:149 E:154 ||| NN
cells  ||| S:154 E:160 ||| NNS
( ||| S:160 E:161 ||| -LRB-
MSCs ||| S:161 E:165 ||| NNP
)  ||| S:165 E:167 ||| -RRB-
from  ||| S:167 E:172 ||| IN
the  ||| S:172 E:176 ||| DT
retropatellar  ||| S:176 E:190 ||| JJ
fat  ||| S:190 E:194 ||| JJ
pad  ||| S:194 E:198 ||| NN
and  ||| S:198 E:202 ||| CC
peripheral  ||| S:202 E:213 ||| JJ
blood  ||| S:213 E:219 ||| NN
has  ||| S:219 E:223 ||| VBZ
been  ||| S:223 E:228 ||| VBN
shown  ||| S:228 E:234 ||| VBN
to  ||| S:234 E:237 ||| TO
stimulate  ||| S:237 E:247 ||| VB
anterior  ||| S:247 E:256 ||| FW
cruciate  ||| S:256 E:265 ||| FW
ligament  ||| S:265 E:274 ||| FW
( ||| S:274 E:275 ||| -LRB-
ACL ||| S:275 E:278 ||| NNP
)  ||| S:278 E:280 ||| -RRB-
fibroblast  ||| S:280 E:291 ||| JJ
proliferation  ||| S:291 E:305 ||| NN
and  ||| S:305 E:309 ||| CC
collagen  ||| S:309 E:318 ||| JJ
production  ||| S:318 E:329 ||| NN
in  ||| S:329 E:332 ||| IN
vitro ||| S:332 E:337 ||| NN
.  ||| S:337 E:339 ||| .
Current  ||| S:339 E:347 ||| JJ
techniques  ||| S:347 E:358 ||| NNS
of  ||| S:358 E:361 ||| IN
bioenhanced  ||| S:361 E:373 ||| JJ
ACL  ||| S:373 E:377 ||| NNP
repair  ||| S:377 E:384 ||| NN
in  ||| S:384 E:387 ||| IN
animal  ||| S:387 E:394 ||| JJ
studies  ||| S:394 E:402 ||| NNS
involve  ||| S:402 E:410 ||| VBP
adding  ||| S:410 E:417 ||| VBG
a  ||| S:417 E:419 ||| DT
biologic  ||| S:419 E:428 ||| JJ
scaffold ||| S:428 E:436 ||| NN
,  ||| S:436 E:438 ||| ,
in  ||| S:438 E:441 ||| IN
this  ||| S:441 E:446 ||| DT
case  ||| S:446 E:451 ||| NN
an  ||| S:451 E:454 ||| DT
extracellular  ||| S:454 E:468 ||| JJ
matrix-based  ||| S:468 E:481 ||| JJ
scaffold  ||| S:481 E:490 ||| JJ
saturated  ||| S:490 E:500 ||| NN
with  ||| S:500 E:505 ||| IN
autologous  ||| S:505 E:516 ||| JJ
whole  ||| S:516 E:522 ||| JJ
blood ||| S:522 E:527 ||| NN
,  ||| S:527 E:529 ||| ,
to  ||| S:529 E:532 ||| TO
a  ||| S:532 E:534 ||| DT
simple  ||| S:534 E:541 ||| JJ
suture  ||| S:541 E:548 ||| JJ
repair  ||| S:548 E:555 ||| NN
of  ||| S:555 E:558 ||| IN
the  ||| S:558 E:562 ||| DT
ligament ||| S:562 E:570 ||| NN
.  ||| S:570 E:572 ||| .
Whether  ||| S:572 E:580 ||| IN
the  ||| S:580 E:584 ||| DT
enrichment  ||| S:584 E:595 ||| NN
of  ||| S:595 E:598 ||| IN
whole  ||| S:598 E:604 ||| JJ
blood  ||| S:604 E:610 ||| NN
with  ||| S:610 E:615 ||| IN
MSCs  ||| S:615 E:620 ||| NNP
would  ||| S:620 E:626 ||| MD
further  ||| S:626 E:634 ||| RB
improve  ||| S:634 E:642 ||| VB
the  ||| S:642 E:646 ||| DT
in  ||| S:646 E:649 ||| IN
vivo  ||| S:649 E:654 ||| JJ
results  ||| S:654 E:662 ||| NNS
of  ||| S:662 E:665 ||| IN
bioenhanced  ||| S:665 E:677 ||| JJ
ACL  ||| S:677 E:681 ||| NNP
repair  ||| S:681 E:688 ||| NN
was  ||| S:688 E:692 ||| VBD
investigated ||| S:692 E:704 ||| VBN
.  ||| S:704 E:706 ||| .
The  ||| S:706 E:710 ||| DT
addition  ||| S:710 E:719 ||| NN
of  ||| S:719 E:722 ||| IN
MSCs  ||| S:722 E:727 ||| JJ
derived  ||| S:727 E:735 ||| NN
from  ||| S:735 E:740 ||| IN
adipose  ||| S:740 E:748 ||| JJ
tissue  ||| S:748 E:755 ||| NN
or  ||| S:755 E:758 ||| CC
peripheral  ||| S:758 E:769 ||| JJ
blood  ||| S:769 E:775 ||| NN
to  ||| S:775 E:778 ||| TO
the  ||| S:778 E:782 ||| DT
blood-extracellular  ||| S:782 E:802 ||| JJ
matrix  ||| S:802 E:809 ||| JJ
composite ||| S:809 E:818 ||| NN
,  ||| S:818 E:820 ||| ,
which  ||| S:820 E:826 ||| WDT
is  ||| S:826 E:829 ||| VBZ
used  ||| S:829 E:834 ||| VBN
in  ||| S:834 E:837 ||| IN
bioenhanced  ||| S:837 E:849 ||| JJ
ACL  ||| S:849 E:853 ||| NNP
repair  ||| S:853 E:860 ||| NN
to  ||| S:860 E:863 ||| TO
stimulate  ||| S:863 E:873 ||| VB
healing ||| S:873 E:880 ||| NN
,  ||| S:880 E:882 ||| ,
would  ||| S:882 E:888 ||| MD
improve  ||| S:888 E:896 ||| VB
the  ||| S:896 E:900 ||| DT
biomechanical  ||| S:900 E:914 ||| JJ
properties  ||| S:914 E:925 ||| NNS
of  ||| S:925 E:928 ||| IN
a  ||| S:928 E:930 ||| DT
bioenhanced  ||| S:930 E:942 ||| JJ
ACL  ||| S:942 E:946 ||| NNP
repair  ||| S:946 E:953 ||| NN
after  ||| S:953 E:959 ||| IN
15  ||| S:959 E:962 ||| CD
weeks  ||| S:962 E:968 ||| NNS
of  ||| S:968 E:971 ||| IN
healing ||| S:971 E:978 ||| NN
.  ||| S:978 E:980 ||| .
Controlled  ||| S:980 E:991 ||| JJ
laboratory  ||| S:991 E:1002 ||| NN
study ||| S:1002 E:1007 ||| NN
.  ||| S:1007 E:1009 ||| .
Twenty-four  ||| S:1009 E:1021 ||| FW
adolescent  ||| S:1021 E:1032 ||| FW
Yucatan  ||| S:1032 E:1040 ||| FW
mini-pigs  ||| S:1040 E:1050 ||| FW
underwent  ||| S:1050 E:1060 ||| FW
ACL  ||| S:1060 E:1064 ||| FW
transection  ||| S:1064 E:1076 ||| FW
followed  ||| S:1076 E:1085 ||| VBN
by  ||| S:1085 E:1088 ||| IN
( ||| S:1088 E:1089 ||| -LRB-
1 ||| S:1089 E:1090 ||| LS
)  ||| S:1090 E:1092 ||| -RRB-
bioenhanced  ||| S:1092 E:1104 ||| VBZ
ACL  ||| S:1104 E:1108 ||| NNP
repair ||| S:1108 E:1114 ||| NN
,  ||| S:1114 E:1116 ||| ,
( ||| S:1116 E:1117 ||| -LRB-
2 ||| S:1117 E:1118 ||| LS
)  ||| S:1118 E:1120 ||| -RRB-
bioenhanced  ||| S:1120 E:1132 ||| VBZ
ACL  ||| S:1132 E:1136 ||| NNP
repair  ||| S:1136 E:1143 ||| NN
with  ||| S:1143 E:1148 ||| IN
the  ||| S:1148 E:1152 ||| DT
addition  ||| S:1152 E:1161 ||| NN
of  ||| S:1161 E:1164 ||| IN
autologous  ||| S:1164 E:1175 ||| JJ
adipose-derived  ||| S:1175 E:1191 ||| JJ
MSCs ||| S:1191 E:1195 ||| NN
,  ||| S:1195 E:1197 ||| ,
and  ||| S:1197 E:1201 ||| CC
( ||| S:1201 E:1202 ||| -LRB-
3 ||| S:1202 E:1203 ||| LS
)  ||| S:1203 E:1205 ||| -RRB-
bioenhanced  ||| S:1205 E:1217 ||| VBZ
ACL  ||| S:1217 E:1221 ||| NNP
repair  ||| S:1221 E:1228 ||| NN
with  ||| S:1228 E:1233 ||| IN
the  ||| S:1233 E:1237 ||| DT
addition  ||| S:1237 E:1246 ||| NN
of  ||| S:1246 E:1249 ||| IN
autologous  ||| S:1249 E:1260 ||| JJ
peripheral  ||| S:1260 E:1271 ||| JJ
blood  ||| S:1271 E:1277 ||| NN
derived  ||| S:1277 E:1285 ||| VBN
MSCs ||| S:1285 E:1289 ||| JJ
.  ||| S:1289 E:1291 ||| .
After  ||| S:1291 E:1297 ||| IN
15  ||| S:1297 E:1300 ||| CD
weeks  ||| S:1300 E:1306 ||| NNS
of  ||| S:1306 E:1309 ||| IN
healing ||| S:1309 E:1316 ||| NN
,  ||| S:1316 E:1318 ||| ,
the  ||| S:1318 E:1322 ||| DT
structural  ||| S:1322 E:1333 ||| JJ
properties  ||| S:1333 E:1344 ||| NNS
of  ||| S:1344 E:1347 ||| IN
the  ||| S:1347 E:1351 ||| DT
ACL  ||| S:1351 E:1355 ||| NNP
( ||| S:1355 E:1356 ||| -LRB-
yield  ||| S:1356 E:1362 ||| NN
load ||| S:1362 E:1366 ||| NN
,  ||| S:1366 E:1368 ||| ,
failure  ||| S:1368 E:1376 ||| NN
load ||| S:1376 E:1380 ||| NN
,  ||| S:1380 E:1382 ||| ,
and  ||| S:1382 E:1386 ||| CC
linear  ||| S:1386 E:1393 ||| JJ
stiffness ||| S:1393 E:1402 ||| NN
)  ||| S:1402 E:1404 ||| -RRB-
were  ||| S:1404 E:1409 ||| VBD
measured ||| S:1409 E:1417 ||| VBN
.  ||| S:1417 E:1419 ||| .
Cell  ||| S:1419 E:1424 ||| NN
and  ||| S:1424 E:1428 ||| CC
vascular  ||| S:1428 E:1437 ||| JJ
density  ||| S:1437 E:1445 ||| NN
were  ||| S:1445 E:1450 ||| VBD
measured  ||| S:1450 E:1459 ||| VBN
in  ||| S:1459 E:1462 ||| IN
the  ||| S:1462 E:1466 ||| DT
repaired  ||| S:1466 E:1475 ||| JJ
ACL  ||| S:1475 E:1479 ||| NN
via  ||| S:1479 E:1483 ||| IN
histology ||| S:1483 E:1492 ||| NN
,  ||| S:1492 E:1494 ||| ,
and  ||| S:1494 E:1498 ||| CC
its  ||| S:1498 E:1502 ||| PRP$
tissue  ||| S:1502 E:1509 ||| NN
structure  ||| S:1509 E:1519 ||| NN
was  ||| S:1519 E:1523 ||| VBD
qualitatively  ||| S:1523 E:1537 ||| VBN
evaluated  ||| S:1537 E:1547 ||| VBN
using  ||| S:1547 E:1553 ||| VBG
the  ||| S:1553 E:1557 ||| DT
advanced  ||| S:1557 E:1566 ||| JJ
Ligament  ||| S:1566 E:1575 ||| NNP
Maturity  ||| S:1575 E:1584 ||| NNP
Index ||| S:1584 E:1589 ||| NNP
.  ||| S:1589 E:1591 ||| .
After  ||| S:1591 E:1597 ||| IN
15  ||| S:1597 E:1600 ||| CD
weeks  ||| S:1600 E:1606 ||| NNS
of  ||| S:1606 E:1609 ||| IN
healing ||| S:1609 E:1616 ||| NN
,  ||| S:1616 E:1618 ||| ,
there  ||| S:1618 E:1624 ||| EX
were  ||| S:1624 E:1629 ||| VBD
no  ||| S:1629 E:1632 ||| DT
significant  ||| S:1632 E:1644 ||| JJ
improvements  ||| S:1644 E:1657 ||| NNS
in  ||| S:1657 E:1660 ||| IN
the  ||| S:1660 E:1664 ||| DT
biomechanical  ||| S:1664 E:1678 ||| NN
or  ||| S:1678 E:1681 ||| CC
histological  ||| S:1681 E:1694 ||| JJ
properties  ||| S:1694 E:1705 ||| NNS
with  ||| S:1705 E:1710 ||| IN
the  ||| S:1710 E:1714 ||| DT
addition  ||| S:1714 E:1723 ||| NN
of  ||| S:1723 E:1726 ||| IN
adipose-derived  ||| S:1726 E:1742 ||| JJ
MSCs ||| S:1742 E:1746 ||| NN
.  ||| S:1746 E:1748 ||| .
The  ||| S:1748 E:1752 ||| DT
only  ||| S:1752 E:1757 ||| JJ
significant  ||| S:1757 E:1769 ||| JJ
change  ||| S:1769 E:1776 ||| NN
with  ||| S:1776 E:1781 ||| IN
the  ||| S:1781 E:1785 ||| DT
addition  ||| S:1785 E:1794 ||| NN
of  ||| S:1794 E:1797 ||| IN
peripheral  ||| S:1797 E:1808 ||| JJ
blood  ||| S:1808 E:1814 ||| NN
MSCs  ||| S:1814 E:1819 ||| NN
was  ||| S:1819 E:1823 ||| VBD
an  ||| S:1823 E:1826 ||| DT
increase  ||| S:1826 E:1835 ||| NN
in  ||| S:1835 E:1838 ||| IN
knee  ||| S:1838 E:1843 ||| JJ
anteroposterior  ||| S:1843 E:1859 ||| JJ
laxity  ||| S:1859 E:1866 ||| NN
when  ||| S:1866 E:1871 ||| WRB
measured  ||| S:1871 E:1880 ||| VBN
at  ||| S:1880 E:1883 ||| IN
30Â°  ||| S:1883 E:1887 ||| CD
of  ||| S:1887 E:1890 ||| IN
flexion ||| S:1890 E:1897 ||| NN
.  ||| S:1897 E:1899 ||| .
These  ||| S:1899 E:1905 ||| DT
findings  ||| S:1905 E:1914 ||| NNS
suggest  ||| S:1914 E:1922 ||| VBP
that  ||| S:1922 E:1927 ||| IN
the  ||| S:1927 E:1931 ||| DT
addition  ||| S:1931 E:1940 ||| NN
of  ||| S:1940 E:1943 ||| IN
adipose  ||| S:1943 E:1951 ||| NN
or  ||| S:1951 E:1954 ||| CC
peripheral  ||| S:1954 E:1965 ||| JJ
blood  ||| S:1965 E:1971 ||| NN
MSCs  ||| S:1971 E:1976 ||| NN
to  ||| S:1976 E:1979 ||| TO
whole  ||| S:1979 E:1985 ||| JJ
blood  ||| S:1985 E:1991 ||| NN
before  ||| S:1991 E:1998 ||| IN
saturation  ||| S:1998 E:2009 ||| NN
of  ||| S:2009 E:2012 ||| IN
an  ||| S:2012 E:2015 ||| DT
extracellular  ||| S:2015 E:2029 ||| JJ
matrix  ||| S:2029 E:2036 ||| JJ
carrier  ||| S:2036 E:2044 ||| NN
with  ||| S:2044 E:2049 ||| IN
the  ||| S:2049 E:2053 ||| DT
blood  ||| S:2053 E:2059 ||| NN
did  ||| S:2059 E:2063 ||| VBD
not  ||| S:2063 E:2067 ||| RB
improve  ||| S:2067 E:2075 ||| VB
the  ||| S:2075 E:2079 ||| DT
functional  ||| S:2079 E:2090 ||| JJ
results  ||| S:2090 E:2098 ||| NNS
of  ||| S:2098 E:2101 ||| IN
bioenhanced  ||| S:2101 E:2113 ||| JJ
ACL  ||| S:2113 E:2117 ||| NNP
repair  ||| S:2117 E:2124 ||| NN
after  ||| S:2124 E:2130 ||| IN
15  ||| S:2130 E:2133 ||| CD
weeks  ||| S:2133 E:2139 ||| NNS
of  ||| S:2139 E:2142 ||| IN
healing  ||| S:2142 E:2150 ||| NN
in  ||| S:2150 E:2153 ||| IN
the  ||| S:2153 E:2157 ||| DT
pig  ||| S:2157 E:2161 ||| NN
model ||| S:2161 E:2166 ||| NN
.  ||| S:2166 E:2168 ||| .
Whole  ||| S:2168 E:2174 ||| JJ
blood  ||| S:2174 E:2180 ||| NN
represents  ||| S:2180 E:2191 ||| VBZ
a  ||| S:2191 E:2193 ||| DT
practical  ||| S:2193 E:2203 ||| JJ
biologic  ||| S:2203 E:2212 ||| JJ
additive  ||| S:2212 E:2221 ||| NN
to  ||| S:2221 E:2224 ||| TO
ligament  ||| S:2224 E:2233 ||| VB
repair ||| S:2233 E:2239 ||| NN
,  ||| S:2239 E:2241 ||| ,
and  ||| S:2241 E:2245 ||| CC
any  ||| S:2245 E:2249 ||| DT
other  ||| S:2249 E:2255 ||| JJ
additive  ||| S:2255 E:2264 ||| NNS
( ||| S:2264 E:2265 ||| -LRB-
including  ||| S:2265 E:2275 ||| VBG
stem  ||| S:2275 E:2280 ||| NN
cells ||| S:2280 E:2285 ||| NNS
)  ||| S:2285 E:2287 ||| -RRB-
should  ||| S:2287 E:2294 ||| MD
be  ||| S:2294 E:2297 ||| VB
demonstrated  ||| S:2297 E:2310 ||| VBN
to  ||| S:2310 E:2313 ||| TO
be  ||| S:2313 E:2316 ||| VB
superior  ||| S:2316 E:2325 ||| JJ
to  ||| S:2325 E:2328 ||| TO
this  ||| S:2328 E:2333 ||| DT
baseline  ||| S:2333 E:2342 ||| NN
before  ||| S:2342 E:2349 ||| IN
clinical  ||| S:2349 E:2358 ||| JJ
use  ||| S:2358 E:2362 ||| NN
is  ||| S:2362 E:2365 ||| VBZ
considered ||| S:2365 E:2375 ||| VBN
.  ||| S:2375 E:2377 ||| .
